Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 10/20 | 0.37 |
| ▸ | PPARA | Q07869 | 10/20 | 0.37 |
| ▸ | PPARD | Q03181 | 9/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341116 | 0.91 | LMNA (0.37) | LMNAHTTS1PR1PPARGPPARA | |
| SCHEMBL4353115 | 0.89 | ABCB1 (0.38) | LMNAHTTS1PR1PPARGPPARA | |
| SCHEMBL13631243 | 0.87 | ABCB1 (0.49) | LMNAHTTS1PR1PPARGPPARA | |
| SCHEMBL6911278 | 0.87 | S1PR1 (0.41) | LMNAHTTS1PR1PPARGPPARA | |
| SCHEMBL4354089 | 0.85 | S1PR1 (0.40) | S1PR1PPARGPPARAPPARDBMP1 | |
| SCHEMBL4347227 | 0.85 | ADAMTS4 (0.46) | LMNAHTTABCB1BMP1ALDH1A1 | |
| SCHEMBL4347715 | 0.84 | LMNA (0.40) | LMNAHTTABCB1BCHEALDH1A1 | |
| SCHEMBL4349451 | 0.84 | TSHR (0.41) | LMNAHTTABCB1ALDH1A1MAPT | |
| SCHEMBL4353025 | 0.84 | ADAMTS4 (0.40) | LMNAHTTABCB1BMP1ALDH1A1 | |
| SCHEMBL13630991 | 0.83 | ABCB1 (0.50) | LMNAHTTS1PR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | LMNA 4130/4885HTT 1847/4885S1PR1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.